Sponsor Pipeline

The United Bio-Technology (Hengqin) Co., Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
6
Active Trials
2
Recruiting
3
Phase 3
5
Disease Areas
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-21 NCT07630233
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of…
Enrollment increased: 43 -> 53 participants
2026-07-21 NCT07630233
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of…
Trial arms changed: 3 -> 4
Active Trials by Phase
Phase 3
3
Phase 2
2
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07648225 UBT251 Injection Phase Ⅲ Study (Overweight or Obesity) Obesity & Overweight Not Yet Recruiting
NCT07653477 Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate… Type 2 Diabetes Not Yet Recruiting
NCT07659574 Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With… Type 2 Diabetes Not Yet Recruiting
Phase 2
NCT07145151 A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis… Metabolic Dysfunction-associated Steatohepatitis (MASH) Recruiting
NCT07134335 UBT251 Injection Phase II Clinical Study (CKD) Obesity & Overweight Recruiting
Phase 1
NCT07630233 A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of… Type 2 Diabetes Mellitus (T2DM) Not Yet Recruiting
Disease Areas
Get alerts when The United Bio-Technology (Hengqin) Co., Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free